Japanese pharmaceutical firm Oncolys BioPharma has officially launched the commercial sales of the world's first viral-based therapeutic drug designed to treat esophageal cancer. According to a report by the Nikkei agency, the release of this product marks a significant milestone in oncology.

The medicine relies on genetically modified oncolytic viruses engineered to target malignant tumors. These viruses replicate within cancer cells to destroy them from the inside while simultaneously activating the body's immune system without causing damage to healthy tissue.

Oncolys BioPharma successfully navigated rigorous regulatory approval procedures before introducing the drug to the market. The certification process was prolonged mainly due to stringent quality control standards required for the mass production of viral agents.

Furthermore, the unique protocol of clinical trials added to the implementation timeline. Unlike conventional cancer treatments, the therapeutic impact of viral therapy requires several weeks to become evident as the agent gradually spreads throughout the tumor mass.